Orokinase Nattokinase Tablets are a dietary supplement containing Nattokinase, a powerful enzyme derived from fermented soybeans (natto). This enzyme is renowned for its potential cardiovascular benefits, particularly in promoting healthy circulation and supporting overall heart health.
Key Features:
- Mechanism of Action: Nattokinase works by breaking down fibrin, a protein involved in blood clotting. This enzymatic activity helps improve blood flow and reduce the risk of clot formation, contributing to cardiovascular wellness.
- Indications: Orokinase Nattokinase is typically used for:
- Supporting healthy blood circulation
- Promoting cardiovascular health
- Assisting in the maintenance of normal blood viscosity
- Dosage: Follow the recommended dosage provided on the packaging or as directed by your healthcare professional. It’s essential to adhere to the suggested intake for optimal results.
- Administration: The tablets should be taken orally with water, preferably on an empty stomach to enhance absorption.
- Side Effects: Nattokinase is generally well-tolerated, but some individuals may experience mild digestive upset or allergic reactions. If you notice any adverse effects, discontinue use and consult your healthcare provider.
- Precautions: Not recommended for individuals taking anticoagulant or antiplatelet medications without medical supervision. Always inform your healthcare provider of your complete medical history and any medications you are currently taking.
Storage: Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.
Note: Orokinase Nattokinase Tablets should be used as a dietary supplement and not as a substitute for a balanced diet or healthy lifestyle. Consult your healthcare professional before starting any new supplement regimen, especially if you have underlying health conditions.
Disclaimer: This description is for informational purposes only and is not intended to provide medical advice or substitute for professional consultation.
Reviews
There are no reviews yet.